APOC3 and chronic kidney disease: As high levels of apoC-III represent a pro-atherogenic risk factor, and apoC-III-lowering agents reduce CV risk (16), the targeting of apoC-III metabolism may become a potential therapeutic approach in preventing CVD in CKD children.